US-based Candid Therapeutics has signed another T-cell engager (TCE ... Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform.

Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from ...

Developed using Simcere’s T-cell engager ... multi-specific biologic candidates in the fields of oncology and immunology. "AbbVie and Simcere Zaiming link to develop trispecific antibody ...

announced today an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics’ proprietary ...

developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and ...

developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and ...

giving Candid exclusive global rights to a preclinical trispecific T-cell engager discovered on WuXi Biologics’ proprietary universal multispecific antibody platform WuXiBody™. WuXi Biologics ...

Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal multispecific antibody ...